Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Time

<< Previous

Bullboard Posts

Next >>

Comment by PlaySafeon Aug 12, 2021 3:19pm

167 Views

Post# 33695370

RE:RE:RE:RE:RE:RE:RE:Time

WalkOver Street --- couldn't agree more, I owned Acasti and had high hopes for them. So Antibe is going from a company ready to start Phase 3 to a company ready to re-do Phase 2 so now we need to pass two trials where placebo-effect could play a role versus only one trial. Thus, grater risk.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market